246 related articles for article (PubMed ID: 14555706)
21. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo.
Shionoya M; Jimbo T; Kitagawa M; Soga T; Tohgo A
Cancer Sci; 2003 May; 94(5):459-66. PubMed ID: 12824894
[TBL] [Abstract][Full Text] [Related]
22. Effects of novel taxanes SB-T-1213 and IDN5109 on tubulin polymerization and mitosis.
Jordan MA; Ojima I; Rosas F; Distefano M; Wilson L; Scambia G; Ferlini C
Chem Biol; 2002 Jan; 9(1):93-101. PubMed ID: 11841942
[TBL] [Abstract][Full Text] [Related]
23. The quest for a simple bioactive analog of paclitaxel as a potential anticancer agent.
Kingston DG; Snyder JP
Acc Chem Res; 2014 Aug; 47(8):2682-91. PubMed ID: 25052294
[TBL] [Abstract][Full Text] [Related]
24. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
[TBL] [Abstract][Full Text] [Related]
25. Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells.
Miyanaga S; Ninomiya I; Tsukada T; Okamoto K; Harada S; Nakanuma S; Sakai S; Makino I; Kinoshita J; Hayashi H; Nakamura K; Oyama K; Nakagawara H; Miyashita T; Tajima H; Takamura H; Fushida S; Ohta T
Int J Oncol; 2016 Feb; 48(2):517-24. PubMed ID: 26676807
[TBL] [Abstract][Full Text] [Related]
26. Semi-synthesis of an O-glycosylated docetaxel analogue.
Nikolakakis A; Haidara K; Sauriol F; Mamer O; Zamir LO
Bioorg Med Chem; 2003 Apr; 11(7):1551-6. PubMed ID: 12628678
[TBL] [Abstract][Full Text] [Related]
27. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
28. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Shirakawa T; Kato K; Nagashima K; Nishikawa A; Sawada R; Takahashi N; Shoji H; Sasaki Y; Honma Y; Iwasa S; Takashima A; Okita N; Hamaguchi T; Yamada Y; Shimada Y
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1207-15. PubMed ID: 25267597
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma.
Imai H; Komine K; Takahashi S; Saijo K; Okada Y; Kobayashi A; Okita A; Chikamatsu S; Kasahara Y; Takahashi M; Oishi T; Shirota H; Takahashi M; Shimodaira H; Ishioka C
Chemotherapy; 2016; 61(5):262-8. PubMed ID: 27043795
[TBL] [Abstract][Full Text] [Related]
30. Chemistry and chemical biology of taxane anticancer agents.
Miller ML; Ojima I
Chem Rec; 2001; 1(3):195-211. PubMed ID: 11895119
[TBL] [Abstract][Full Text] [Related]
31. The use of a novel taxane-based P-glycoprotein inhibitor to identify mutations that alter the interaction of the protein with paclitaxel.
Gruol DJ; Bernd J; Phippard AE; Ojima I; Bernacki RJ
Mol Pharmacol; 2001 Jul; 60(1):104-13. PubMed ID: 11408605
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel and docetaxel in prostate cancer.
Obasaju C; Hudes GR
Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
[TBL] [Abstract][Full Text] [Related]
33. Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel.
Fromes Y; Gounon P; Veitia R; Bissery MC; Fellous A
J Protein Chem; 1996 May; 15(4):377-88. PubMed ID: 8819014
[TBL] [Abstract][Full Text] [Related]
34. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.
Hill BT; Whelan RD; Shellard SA; McClean S; Hosking LK
Invest New Drugs; 1994; 12(3):169-82. PubMed ID: 7896535
[TBL] [Abstract][Full Text] [Related]
35. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and structure-activity relationships of novel 2',2'-difluoro analogues of docetaxel.
Uoto K; Ohsuki S; Takenoshita H; Ishiyama T; Iimura S; Hirota Y; Mitsui I; Terasawa H; Soga T
Chem Pharm Bull (Tokyo); 1997 Nov; 45(11):1793-804. PubMed ID: 9396156
[TBL] [Abstract][Full Text] [Related]
37. Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo.
Wang H; Li H; Zuo M; Zhang Y; Liu H; Fang W; Chen X
Cancer Lett; 2008 Sep; 268(1):89-97. PubMed ID: 18482796
[TBL] [Abstract][Full Text] [Related]
38. Orally active docetaxel analogue: synthesis of 10-deoxy-10-C-morpholinoethyl docetaxel analogues.
Iimura S; Uoto K; Ohsuki S; Chiba J; Yoshino T; Iwahana M; Jimbo T; Terasawa H; Soga T
Bioorg Med Chem Lett; 2001 Feb; 11(3):407-10. PubMed ID: 11212122
[TBL] [Abstract][Full Text] [Related]
39. Dissecting paclitaxel-microtubule association: quantitative assessment of the 2'-OH group.
Sharma S; Lagisetti C; Poliks B; Coates RM; Kingston DG; Bane S
Biochemistry; 2013 Apr; 52(13):2328-36. PubMed ID: 23473345
[TBL] [Abstract][Full Text] [Related]
40. Designing and Testing of Novel Taxanes to Probe the Highly Complex Mechanisms by Which Taxanes Bind to Microtubules and Cause Cytotoxicity to Cancer Cells.
St George M; Ayoub AT; Banerjee A; Churchill CD; Winter P; Klobukowski M; Cass CE; Ludueña RF; Tuszynski JA; Damaraju S
PLoS One; 2015; 10(6):e0129168. PubMed ID: 26052950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
